Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm...
Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma...
Merck KGaA Partners with Roche to Commercialize Tepmetko in China
Germany-based pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a partnership with Swiss giant...
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial...
GSK’s Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) announced that it has received marketing approval from...
Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s...
WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Sanofi’s Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis
Sanofi (EPA: SAN, NASDAQ: SNY) announced that a market filing for its tolebrutinib as a...
Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024...
Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its Q4 2024 financial results....
China’s 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation
The Pharmacopoeia of the People’s Republic of China (2025 Edition), released by the National Medical...
Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with...
Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical...
Chia Tai Tianqing’s TQB2210 Approved for Advanced Malignant Tumor Study
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved...
CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access
China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical...
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...
Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced a license agreement with US-based giant Merck...
Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National...
Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...
Fapon Biotech Partners with Sansure to Develop Next-Generation Diagnostic Solutions
China-based biotech Fapon Biotech Inc. has formed a strategic partnership with molecular diagnostics specialist Sansure...